CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, Seaport

Positive
AI Analysis

Summary

Celea Therapeutics, a PureTech portfolio company focused on idiopathic pulmonary fibrosis, has secured $180 million in funding from new investors to advance its pipeline programs.

Importance:6/10
Sentiment:
0.60
IPFfundingSeries B or laterPureTech portfolio
Related Companies

Read the original article

Published by Endpoints News on July 2, 2026 2:28 PM

Read Original